EVC2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P04861(EVC2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04861(EVC2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The EVC2 antibody is designed to target the EVC2 (Ellis-van Creveld syndrome 2) protein, encoded by the *EVC2* gene located on human chromosome 4p16. EVC2. along with EVC, forms a complex critical for proper skeletal development and cilia function. Mutations in *EVC2* are linked to Ellis-van Creveld syndrome (EVC), a rare autosomal recessive disorder characterized by skeletal dysplasia, polydactyly, cardiac defects, and dental anomalies. EVC2 localizes to the base of primary cilia and plays a role in Hedgehog (Hh) signaling, a pathway essential for embryonic patterning and tissue homeostasis. Specifically, the EVC-EVC2 complex modulates non-canonical Hh signaling by regulating the trafficking of Smoothened (SMO), a key transducer of Hh signals.

Antibodies against EVC2 are vital research tools for studying ciliopathies and skeletal development disorders. They enable detection of EVC2 expression in tissues or cell lines via techniques like Western blotting, immunofluorescence, and immunohistochemistry. These antibodies help elucidate EVC2’s subcellular localization, interaction partners, and functional roles in ciliary signaling. Additionally, they aid in diagnosing EVC syndrome and understanding genotype-phenotype correlations. Commercial EVC2 antibodies are typically raised against specific epitopes, often validated for specificity in knockout models. Research using these reagents contributes to uncovering molecular mechanisms underlying cilia-related pathologies and potential therapeutic targets.